Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing atrial fibrillation recurrence after catheter ablation.
Stachteas P, Karakasis P, Karagiannidis E, Patoulias D, Athanasiadou P, Nasoufidou A, Papadopoulos C, Kassimis G, Fragakis N. Stachteas P, et al. Among authors: patoulias d. Hellenic J Cardiol. 2024 Sep-Oct;79:86-87. doi: 10.1016/j.hjc.2024.03.008. Epub 2024 Mar 12. Hellenic J Cardiol. 2024. PMID: 38484841 Free article. No abstract available.
Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure.
Koutsampasopoulos K, Vogiatzis I, Ziakas A, Papadopoulos C, Imprialos KP, Stavropoulos K, Katsimardou A, Patoulias D, Bakogiannis C, Vasilikos V, Karagiannis A, Doumas M. Koutsampasopoulos K, et al. Among authors: patoulias d. J Sex Med. 2019 Aug;16(8):1199-1211. doi: 10.1016/j.jsxm.2019.04.012. Epub 2019 May 24. J Sex Med. 2019. PMID: 31133422
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D, Stavropoulos K, Imprialos K, Katsimardou A, Kalogirou MS, Koutsampasopoulos K, Zografou I, Papadopoulos C, Karagiannis A, Doumas M. Patoulias D, et al. Diabetes Res Clin Pract. 2019 Dec;158:107927. doi: 10.1016/j.diabres.2019.107927. Epub 2019 Nov 13. Diabetes Res Clin Pract. 2019. PMID: 31733280
Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D, Katsimardou A, Kalogirou MS, Zografou I, Toumpourleka M, Imprialos K, Stavropoulos K, Stergiou I, Papadopoulos C, Doumas M. Patoulias D, et al. Diabetes Metab. 2020 Sep;46(4):272-279. doi: 10.1016/j.diabet.2020.04.001. Epub 2020 May 8. Diabetes Metab. 2020. PMID: 32437914
296 results